Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kinan Mokbel"'
Autor:
Fahad Alghamdi, Kinan Mokbel, Robert Meertens, Abasiama Dick Obotiba, Mansour Alharbi, Karen M. Knapp, William David Strain
Publikováno v:
Viruses, Vol 16, Iss 11, p 1694 (2024)
SARS-CoV-2 is highly transmissible and affects the respiratory system. People with COVID-19 are at higher risk of physical and mental health conditions, which could impact bone health. The aim of this review was to explore the effects of COVID-19 on
Externí odkaz:
https://doaj.org/article/95cbe25ae22841c2af869b0be246eb92
Publikováno v:
Cellular & Molecular Biology Letters, Vol 22, Iss 1, Pp 1-7 (2017)
Abstract Background Clinicians use clinical and pathological parameters, such as tumour size, grade and nodal status, to make decisions on adjuvant treatments for breast cancer. However, therapeutic decisions based on these features tend to vary due
Externí odkaz:
https://doaj.org/article/276adae003734742a38f5443376b14bc
Autor:
Kinan, Mokbel, Kefah, Mokbel
Publikováno v:
Anticancer Research. 42:661-666
Breast cancer is the most common cancer in women globally. To prevent relapse and prolong disease-free survival, adjuvant endocrine treatment such as selective oestrogen receptor modulators and aromatase inhibitors are being used. However, such oestr
Publikováno v:
Anticancer Research. 42:1013-1018
Improvements in acellular dermal matrix (ADM) and surgical techniques have facilitated pre-pectoral immediate breast reconstruction (IBR). Outer shell texturing is a key risk factor for anaplastic large cell lymphoma, prompting this evaluation of rec
Publikováno v:
In Vivo
Background/Aim: Adverse drug reactions (ADRs) represent a major concern leading to significant increases in both morbidity and mortality globally. Providing healthcare professionals (HCPs) and patients with real-world data on drug safety is imperativ
Publikováno v:
Anticancer research. 38(8)
The Nottingham Prognostic Index (NPI) was developed using tumour pathological features to guide decisions regarding adjuvant therapy in breast cancer. Recent breakthroughs in molecular biology aided development of genomic assays such as EndoPredict,